Cue Biopharma prices $12M public offering of stock and warrants, extends cash runway into Q4 2025

Cue Biopharma, Inc.

10.6M shares of common stock and 2.9M common stock warrants offered at $0.50 per unit; pre-funded warrants for 12.4M shares at $0.499.
Net proceeds estimated at $10.7M after underwriting discounts and expenses.
Oppenheimer & Co. is sole book-running manager; closing expected September 30, 2024.
Cash runway extended into fourth quarter of 2025, based on current plans.
Warrants: pre-funded exercisable at $0.001, common stock warrants at $0.50, expire in five years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.